ProxiCube - the device helps schools comply with their ventilation concepts

Campus report with news from the university in Mannheim. Aerosols from the air we breathe are considered to be the greatest risk factor for infection with the SARS-CoV2 coronavirus. Especially in poorly ventilated indoor spaces - for example in schools and similar facilities - there is a risk that the tiny droplets from the air we breathe will collect and spread the virus, which is why strict ventilation concepts now apply in many public places. However, the aerosol concentration has not yet been monitored. Researchers at the Mannheim University of Applied Sciences have now faced this and have found a solution for which a patent has now been applied: an aerosol detector.

Air quality and health always in view - Mannheim University of Applied Sciences develops aerosol detectors

Aerosols from the air we breathe are considered to be the greatest risk factor for infection with flu viruses and, among other things, the coronavirus SARS-CoV2. The CeMOS competence center (Center for Mass Spectrometry and Optical Spectroscopy) at the Mannheim University of Applied Sciences has developed a special measurement technology and has applied for a patent to guarantee effective and precise measurement of aerosols in the room air. In poorly ventilated interiors, especially in the winter period, there is a risk that tiny droplets from the air you breathe will collect and that viruses will spread more quickly, which is why strict ventilation regulations now apply in many public places, especially in schools and companies. In addition to viruses, other particles such as pollen, allergens and pollutants make life more difficult in many places. About two years ago, CeMOS developed a handy system - hardly bigger than a magic cube - for measuring aerosols indoors. It uses a sensor that was originally intended for the determination of fine dust concentrations and was developed as part of the FH impulse funding M2Aind.

Rubik's cube for air purity

The M2Aind cooperation partner, the company ProxiVision GmbH in Bensheim, has recently started producing the first prototypes under the brand name ProxiCube, the size and shape of which correspond to a Rubik's cube. The schools in Mannheim have shown great interest and the economic development of the city of Mannheim is promoting the development and application within the framework of the Smart Production / Industry 4.0 innovation network. If everything goes according to plan, the first classrooms can be equipped with ProxiCubes as early as the beginning of 2021. The Werner von Siemens School on the Neckarpromenade is the first school that will have some cubes in use as early as January.

Technology, design and sales made in Mannheim

Last weekend, the Mannheim technology startup Nevoox Europe GmbH, which specializes in innovative hygiene solutions, has been able to win a strong sales partner. Nevoox recently started developing UV-C light-based disinfection solutions for indoor air and surfaces, among other things, and will be exclusively responsible for selling ProxiCubes throughout Germany and internationally. The magic cube for air purity is launched on the market under the name “Nevoox ProxiCube²”. It will be available in different versions from mid-January.

There will even be a special “Mannheimer Würfel” edition, which of course includes the Mannheim square theme and the unique color ensemble of the city of Mannheim reflects. Additional different model variants are planned - from the basic model to an exclusive high-end version with a contactless Qi charging function and high-quality housing materials.

The “Mannheim Cube” can continuously measure numerous important values ​​on air quality and transmit them to users such as school principals, building managers, operations managers or even in private households on a dashboard or applications such as mobile phone apps.

"Hotels, bus companies, restaurants and many other industries can also use this technology for the safety and well-being of employees and guests," says Thomas Walch, Managing Director of Nevoox. “Up to now, a large number of sensors were necessary to determine so much data from the room air. The fist-sized ProxiCube takes care of all of this and also draws in the air independently through a small fan in order to analyze it. "

Depending on customer requirements, the Nevoox ProxiCube² can also be supplied as an OEM product with various measurement configurations. The Nevoox ProxiCube² works with all common radio systems and can be effortlessly integrated into cloud systems and can therefore also be optimally used as a trigger for e.g. an IoT-controlled air filter. This means that there are no application limits for the system, be it as an isolated solution for schools, companies, or as a control and information unit for building management solutions.

If you want to find out more about the development made in Mannheim, you can find initial information on the Nevoox Europe GmbH website www.nevoox-europe.com​​​​​​​

 

Nevoox-Europe

The startup based in Mannheim, founded in July 2020, sells and produces high-quality and innovative products and solutions for disinfection in the medical, public, private and commercial sectors. In addition to standardized sterilization / disinfection in hospitals and similar environments, surface disinfection - not least due to the current COVID-19 situation - has become very important in all areas of daily life. Nevoox therefore offers suitable hygiene solutions and disinfection concepts for different scenarios: from offices to cosmetic studios, sports facilities, day-care centers and shops. Nevoox Europe works with well-known manufacturers such as Planlicht and DellaSolare as well as institutions from the public sector and hospital associations and also with a strong network in the office world and consumer electronics Nevoox Europe also has its own research and sourcing office in Asia. In addition, Nevoox Europe GmbH operates its own mask production in the metropolitan region of Manila, which produces on-site according to German standards and with European management. The production site and the products meet the quality criteria of TÜV Rheinland. The young company is already represented in over ten countries with affiliated partner companies. With the support of a worldwide cooperation network, Nevoox Europe now supplies customers in a wide variety of industries.

ProxiVision

ProxiVision GmbH is a medium-sized company that manufactures electro-optical detectors for various applications in the civil and military sectors. The core competence lies in the development and production of image intensifiers, which are particularly sensitive in the ultraviolet and visible spectral range, as well as the integration of these components in detector units and cameras or camera systems. In addition, the company has extensive specialist knowledge from a long history of development and production. ProxiVision secures its know-how through its own design and a high production depth. The company has a special interest in developing opto-electronic product innovations in close cooperation with customers and partners and bringing them to market maturity. Our future activities will increasingly include applications and requirements in the life science and analytical market.

Stadt Mannheim / Netzwerk Smart Production / CeMoS der Hochschule Mannheim

The city of Mannheim promotes the pioneering and developer spirit of its universities and companies through an active innovation policy. To this end, the Mannheim Economic Development Corporation initiated the Smart Production network as a central innovation cluster for smart technologies in the Rhine-Neckar metropolitan region. The development of the “MannheimCube” is a key project on the way to becoming a Smart City. The project opens up the possibility of meeting current challenges from Covid-19 to climate protection worldwide and was created in cooperation with the CeMOS research center of the Mannheim University of Applied Sciences with many other of the around 50 network partners. Business development and schools are pilot customers of the “Mannheim Cube”.

Mannheim University of Applied Sciences develops aerosol detectors - the device helps schools comply with their ventilation concepts

The competence center CeMOS (Center for Mass Spectrometry and Optical Spectroscopy) at the Mannheim University of Applied Sciences is developing a handy system for measuring aerosols indoors. It uses a sensor that was originally intended for the determination of fine dust concentrations and was developed as part of the FH impulse funding M2Aind. The M2Aind cooperation partner, the company ProxiVision GmbH in Bensheim, is now producing the first prototypes under the working title ProxiCube and is already in negotiations with the corresponding sales partners. The schools in Mannheim have shown great interest and the economic development of the city of Mannheim is promoting the development and application within the framework of the innovation network Smart Production / Industry 4.0; if everything goes well, the first classrooms can be equipped with ProxiCubes as early as the beginning of 2021. The Werner von Siemens School on the Neckarpromenade is the first school that has already ordered five cubes from Proxivision.

Aerosols from the air we breathe are considered to be the greatest risk factor for infection with the SARS-CoV2 coronavirus. Especially in poorly ventilated indoor spaces, especially in winter, there is a risk that the tiny droplets from the air you breathe will collect and spread the virus - which is why strict ventilation concepts now apply in many public places and especially in schools. But there is always some uncertainty: Has the room really been ventilated thoroughly enough? When does the aerosol concentration become critical, and can't you dare to keep the window closed for a while? CeMOS researcher Dr. Thomas Schäfer and converted a battery-operated, portable device for fine dust measurement he helped develop a few years ago into an aerosol detector. He explains why this is so easy: “The optical sensor makes no difference between dust particles and tiny drops of liquid. It counts every particle between 300 nanometers and 10 micrometers in size that passes the light barrier inside. "

Schäfer and his team therefore use the same sensors for the aerosol detector as for fine dust measurement, but in a double pack: One sensor simply measures the room air that is sucked in, the second heats the air that is sucked in so that liquids evaporate. From the difference between the two measurements, the device then calculates the amount of watery droplets that are in the air - so it can reliably differentiate between solid and liquid particles. The measured data are output to the user so that the aerosol concentration can be observed and documented over longer periods of time; In addition, the development team is planning a dashboard on which several rooms can be monitored via a traffic light system and which issues a warning as soon as too many aerosols collect in a room. ProxiCube has since been applied for a patent.

News from M²Aind- the industrial partnership for innovations in the health industry

Impressions of the M²Aind Symposium 2020

The M²Aind symposium at Mannheim University of Applied Sciences met with keen interest, which took place for the second time this year. The symposium is a user-oriented event that focuses on innovations and innovative development approaches for laboratory automation. At the forefront, current and innovative developments from M²Aind and their industrial partnership for innovations were presented in cooperation between the partner companies. Over two days, over 100 representatives from business and science attended the meeting of this kind. The program offered the audience a variety of innovative contributions from the M²Aind partnership and a win to speakers from well-known companies such as AbbVie, Analytik Jena, BASF, Boehringer Ingelheim, BRAIN, hte, InnoSyn, Leica Mikrosysteme, Merck, Novartis, Roche. The M²Aind young scientists also had their say in each of the two subject areas and presented their latest findings.

Day 1, 4.2.2020
Microreactors and continuous synthesis, online spectroscopy process analysis.
Chemical active ingredient production is in a constant competitive situation in Europe. In order to assert itself on the world market, it is necessary for the process industry to have excellent processes with a technically innovative solution. For this purpose, trend-setting approaches were presented at the symposium. Through the use of innovative microreactor technology and online spectroscopy, it has been possible to develop a set-up that optimizes a chemical process completely autonomously without the intervention of a chemist. Overall, automation, micro reaction technology and sophisticated new analysis methods such as ion mobility spectroscopy were the central theme throughout all lectures. All of these innovative approaches were discussed intensively and lively with the industrial partners. The key note lecture by Prof. Dr.-Ing. Norbert Kockmann, Technical University Dortmund with the topic "Smart Process Equipment in the laboratory". A long-term research cooperation exists between Professor Koopmann and Mannheim University of Applied Sciences, which has already resulted in numerous joint publications and doctorates. Representatives of the companies BASF, hte, InnoSyn, Novartis report on the use of microreactors and modern tools for process development in industry. In the late afternoon, the participants expected a tour of the brewery through the Eichbaum brewery in Mannheim. The day ended with a dinner together. Here you get an insight into the program.

Day 2, 5.2.2020
Topic: Innovative Compound Profiling Technologies: Label-free MALDI-MS assays.
MALDI mass spectrometry is today an indispensable tool in industrial research, development and production as well as in the academic application-related basis. Due to the versatility of the method, there is an abundance of different starting points that form the basis for application-oriented projects with cooperation partners from industry and academy. Representatives of Boehringer Ingelheim, Roche, Analytik Jena and the project teams reported on the various aspects, challenges, advantages and expected future developments. A wide range of questions were raised. MALDI MS based cellular assays, which have been used both in the identification of inhibitors in fatty acid synthesis and also serve as the basis for the determination of inhibitors of transport proteins, which also play a role in possible drug interactions. The use of the method in the drug discovery process was supported by the high throughput sequencing (HTS) usability of the method. Concrete examples of this application were shown above all by Analytik Jena, whose devices guarantee the possibility of HTS primarily through automation in the laboratory. The use of MALDI as a high throughput method in the lead discovery at Roche was also particularly interesting for the participants. The participants particularly praised the cooperation between industrial partners and academic partners when working on various projects in the M2Aind Alliance. Here you get an insight into the program.

Topic: Innovative Compound Profiling Technologies: 3D microscopy in 3D cell cultures.
The main topic is of outstanding importance, as the focus of M²Aind includes research on methods of multimodal tissue analysis as well as the production and use of tissue preparations and complex cell cultures stands for drug discovery and pathology of the future. The innovative approach of the project is to combine traditionally used methods with the new and rapidly growing possibilities of three-dimensional imaging, digital analysis and to process the data obtained in this way at a higher level of knowledge and to use them for the desired research purposes. The aim of the project is to develop highly integrated applications for various complex problems in the pharmaceutical and medical technology industry together with industrial partners. Representatives of AbbVie Deutschland, Merck, BRAIN, Leica Mikrosysteme and from the project teams reported on various aspects, challenges, advantages and expected future developments. A wide range of questions were addressed: choice and differentiation of cell types to be used, 3D bioprinting, optical tissue clearing, 3D visualization with perfusion of active ingredients, new methods of functional microscopy. The lectures were rounded off with concrete examples for application to substance testing. In this respect, the entangled presentation of methodological challenges and solutions with current issues from industry was a special feature of the event. Based on this, there were exciting discussions and interactions among the conference guests present. Here you get an insight into the program.

Quotes from the participants of the M²Aind Symposium 2020

"I attended both symposium days. The quality and originality of the lectures was just as convincing as the open discussion culture. Congratulations to the organizers of this symposium." Peter Kilz, PSS Polymer Standards Service GmbH

"The presentations were very interesting. The value for me is in the applicability of the know-how. I will recommend the symposium to my colleagues in flow chemistry. ” Raf Reintjens, InnoSyn B.V.

After the extremely positive feedback on the event, we look forward to the next M²Aind Symposium 2021. The date will be announced as soon as possible. Further information on the research projects can be found at: https://www.m2aind.hs-mannheim.de/en/projects.html

 

M²Aind Scientist wins poster award in Budapest

From October 16 to 18, 2019, the 7th Conference on Frontiers in Organic Synthesis Technology took place in Budapest. M²Aind scientist Clarissa Benzin, who works within M²Aind on the project SM²all won the cash rewarded Best Poster Award with her poster Methylation with Chloromethane in a Microreactor. A total of 23 posters by junior scientists were presented. The Poster Committee will only include posters presenting current research findings and current topics that have produced promising preliminary results. Ms. Benzin received her award during the evening gala dinner on a boat on the river Donau.

7. M²Aind Talk - Edge Intelligence and Medical Technology

We are happy to be part of the 1st Mannheim Innovation Festival "innomake"! The purpose of the festival is to initiate a new social and economic discourse on the significance of sustainable innovations.

From 14.10. until 27.10.19 companies, institutions, the culture and the start-up scene in Mannheim come together. More than 15 events: Whether input session, hackathon, workshop, conference or accompanying exhibitions - in addition to established events are also many new formats on the program.

7. M²Aind Talk - Edge Intelligence and Medical Technology
10/22/19 - This is the seventh M²Aind Talk, this time as part of the Innovation Festival. It is a get-together of the health industry for the metropolitan area of ​​Rhein-Neckar-Main.

The two speakers Marcus Götz (MRC Systems Heidelberg) and Professor dr. Marcus Vetter (M²edTech, Mannheim University of Applied Sciences) addressed the topics of edge intelligence and medical technology in their keynote speeches. After the lectures, the ESM institute (Institute for Embedded Systems, Control and Medical Technology) visited Professor Vetter, where the participants learned more about deep learning in medical technology.

After the very successful lectures, the subsequent networking took place at Fingerfood and Drinks. Once again, the regional representatives of the life sciences industry to exchange views and learn new things.

Nach den sehr erfolgreichen Vorträgen fand das anschließende Networking bei Fingerfood und Drinks statt. Auch diesmal trafen sich die regionalen Vertreter der Life Science Industrie, um sich auszutauschen und Neues zu erfahren.

Further information about the research projects can be found here.

Festival in Mannheim: A high on the inventor city

14th to 27th of October a festival. "Innomake!"

New accents and proven event formats
The "innomake!" Is made up of 15 events. And a glance at the program reveals that not everything has to be reinvented for the very complex and specialist festival. Many tried and tested formats such as the Urban Thinkers Campus (24th to 26th October in the town house N1), the Design Industry Expo (23rd October in the C-HUB) or the medical-oriented "M2Aind-Talk" (22nd October at the university Mannheim) are due to gain a new visibility in the joint performance. And also the social thought should be lived. For example, at the "Nachtschicht" on 16 October in the Alte Volksbad, Mannheim designers and marketing strategists will make their expertise available to nonprofit organizations for a free eight-hour shift.

Most social and environmental festival conventions are reserved for a specialist audience. Under the motto "Innovations made in Mannheim", however, a three-part exhibition on Paradeplatz, at the main station and at the Augustaanlage will appeal to nearly every visitor to Mannheim from 7 October. At "Women in Tech" on October 22 at the N7, the focus is on the role of women in technical occupations. The "Climathon" (25th to 27th October) also provides an opportunity to become a participant in the event and possibly a suspected patent inventor when an ideas competition on climate protection is proclaimed at Mafinex. More information is available here.

(Source: Die Rheinpfalz)

M²Aind Symposium 2019

24.6.-25.6.19

Innovation Partnership M²Aind looks back on the successful M²Aind Symposium 2019 on "Microreactors and Continuous Synthesis, Online Spectroscopy and Process Analytics".

 

Highlights of the 2-day program:

Day 1, 24.6.19

The workshop, at the University of Mannheim, under the topic "Process Fundamentals of Microreactors", under the direction of Prof. Dr. Röder, was booked with great interest. In the late afternoon the participants expected a city tour through Mannheim "Into the World of known Pioneers". The day ended with a dinner at Palm's Pacific Lounge restaurant in Mannheim.

Day 2, 25.6.19

On the day of the M²Aind Symposium the participants expected exciting lectures and news from process development and process analysis. M²Aind employees of HS Mannheim and companies from the pharmaceutical industry were given the opportunity to report on current developments. Particularly interesting for the participants was the mixture of current research results of the university and application reports of the industry representatives.

The topics covered the entire spectrum of modern chemical process development. The participants particularly praised the intensive use of online analytics and the high degree of automation and digitization of the research project in the M²Aind Alliance. Representatives of BASF, Novartis, Merck and ONE-A report on the use of microreactors and advanced process development tools in the industry. Here is an insight into the M²Aind Symposium 2019 agenda.

Participants' comments:

"A very well-organized event, from which I have taken a variety of technical and scientific inspiration for my daily work at Merck."

Mr. Philipp Lau, Merck KGA

"Thanks again for the invitation, the whole thing was very interesting because all participants had more or less the same interests."

Dr. Julien Haber, Novartis Pharma AG

After the very positive feedback on the event, we look forward to the next M²Aind Symposium 2020. The date will be announced as soon as possible. Further information on the research projects can be found at: https://www.m2aind.hs-mannheim.de/projekte.html

Annual report of the Carl Zeiss Foundation for the financial year 2017/2018

MALDI Innovations in Pharma 2019

Bruker’s and M²Aind’s 2nd Mannheim Symposium “Mass Spectrometry and Surface Plasmon Resonance (SPR) Innovations in Pharma”

In cooperation with partner Bruker Daltonik GmbH, the innovation partnership M²Aind organised the second congress "Bruker's and M²Aind's VIP Day 2019" at the University of Mannheim from 18.-19. March 2019.

Over two days, around 120 industry and academia representatives from pharmaceutical, diagnostics, chemistry, medical technology and biotechnology sectors took the opportunity to network and share the latest research findings.

The event focused on new label-free technologies for pharmaceutical research and development: pharmaceutical applications of MALDI MS Imaging as well as MALDI PharmaPulse for high-throughput screening using MALDI mass spectrometry, surface plasmon resonance for compound profiling and NMR spectroscopy for fragment-based screening. There was a great deal of interest among the audience in the wide range of current application areas, which were presented by the speakers in around 20 lectures.

The speakers came from research companies and scientific institutions such as:

Bayer (Germany), Boehringer Ingelheim (Germany), Bruker (Germany), ETH Zürich (Switzerland), Evosep (Denmark), CeMOS (Germany), Harvard Medical School (USA), GlaxoSmithKline (UK), Merck (Germany), Newcastle University (UK), Osaka University (Japan), Roche (Switzerland), Servier (France).

Professor Carsten Hopf, initiator of the event and director of the research center CeMOS - Center for Mass Spectrometry and Optical Spectroscopy in Mannheim, invited interested people to a tour through the BMBF and DFG funded Rhein-Neckar Center for MS Imaging and MS Assays. Professor Hopf looks back with satisfaction on a successful congress with international lectures: "An international congress for MALDI mass spectrometry tailored to the interests of the pharmaceutical industry - label-free assay technologies on the one hand and mass spectrometric imaging for DMPK and toxicology on the other hand hasn't taken place in Germany so far. The great response shows the need for these technologies, and I am glad that Bruker has organized such an event with M²Aind."

Vice Rector for Research and Technology Transfer of the University of Mannheim, Professor Mathias Hafner, assesses the event as a complete success for the innovation partnership M²Aind: "Due to the great interest of the industry in this event, we feel confirmed that we have set the right priorities in research; we are internationally competitive at the highest level." The detailed program can be found here Day 1 / Day 2

Three awards for the Innovation Partnership M²Aind in the competition „Ideenwettbewerb Biotechnologie“

Since 2016, the University of Applied Sciences Mannheim has been one of the ten Universities of Applied Sciences awarded by the Federal Ministry of Research for special research excellence with the so-called FH Impulse Innovation Partnership M²Aind "Multimodal Analytics and Intelligent Sensorics for the Healthcare Industry".

The university of Applied Sciences was able to prevail in a fierce competition and achieve funding from Berlin in the amount of initially € 5 million and an additional € 1.3 million from the industry. Three partners of the innovation partnership from the impulse project "SM²all" are among the recipients of the nationwide biotechnology competition, they convinced the external jury with their three submitted project proposals.

With this idea competition, the Ministry of Science and Art of Baden-Württemberg wants to promote research approaches that are characterized by original new solution strategies with a high scientific-technical success and development risk and are not associated with pure basic research or market-related research. Each of the winners of the competition will initially receive a grant of up to € 60,000 to conduct a nine-month feasibility study.

"We are very happy about this triple award", says Prof. Dr. Thorsten Röder, head of SM²all, who, together with Prof. Philipp Weller, was given the opportunity to prepare a feasibility study by the middle of this year. "These grants make it clear once again how high the creative capability of our innovation partnership is", emphasizes Prof. Dr. med. Carsten Hopf, Partner spokesman of M²Aind and head of the competence center CeMOS at the University of Mannheim. In the future, the CeMOS competence center will develop new evaluation techniques for microarrays together with the Karlsruhe Institute of Technology in the two other funded projects in order to advance key technology advances in efficiency enhancement, automation and cost reduction.

The aim of the impulse project SM²all is the modernization of the entire process chain of pharmaceutical production for small molecules and biopharmaceuticals.The main goal is to use an innovative combination of automation technology and online analysis to produce active ingredients in a continuously secured process and to test their function in order to increase patient safety and reduce manufacturing costs.

 

M²Aind Retreat 2018

From 15. to 16. October 2018 the M²Aind Retreat took place for the first time, in which industrial partners from the health sector and members of the Mannheim University of Applied Sciences participated.

The conference took place at the Ebernburg  in the Bad Kreuznach district of Bad Münster am Stein. In good weather, 52 participants took the opportunity to get a deeper insight into the M²Aind projects, to get to know the M²Aind team and the other project partners.

The first day started in the afternoon with a greeting from M²Aind partner spokesman Professor Dr. Carsten Hopf, who warmly welcomed the participants to the first M2Aind Retreat.An essential part of the agenda was the presentation of the impulse projects SM2all, M²OGA and M²edTech, which were described in detail by the project leaders Professor Dr. Thorsten Röder (SM²all), Professor Dr. Rüdiger Rudolf (M²OGA) and Professor Dr. Matthias Rädle (M²edTech) were presented.
 

Company presentations took place in the second part of the day. The aim was to find out more about our industrial partners and their project work and to find points of contact for possible cooperation in the future. We thank Dr. Katharina Cuk, BioNTech AG, Dr. Jens Fuchser, Bruker Daltonics GmbH, Dr. Dennis Reibel, Freudenberg Technology Innovation SE & Co KG, Dr. Anne Arnold, Immunodiagnostics AG, Mrs. Stefanie Szmais & Dr. Richard Schneider, Merck KGaA, Dr. Marcus Götz, MRC Systems GmbH, Professor Dr. Rolf-Jürgen Ahlers, ProxiVision GmbH, Dr. Vanya Todorova, Roche Diabetes Care GmbH, Dr. Norbert-Karl Egger, Sanofi-Aventis Germany GmbH, Dr. Friedrich Reinhard, GSK GmbH for their successful short pitches.

After the group special, a guided tour of the Ebernburg or a tour through the city of Bad Münster am Stein, the participants returned to the evening in the Ebernburgschänke. In a poster session, our project team presented their results to date in cooperation with their project partners. The project work and the exchange of all involved were the main focus of the evening. Everyone involved uses the opportunity to get to know each other better and to exchange ideas with other M²Aind partners across projects.

On the second day the poster session of the first day in the Ebernburgschänke was continued. This was followed by a review of the first day of the conference.At this point, we would like to thank our guest spokeswoman, Dr. Vanaya Todorova (Roche Diabetes Care GmbH) for a summary of the key points of the first day of the conference. It continued with the podium discussion conducted by Professor Dr. Mathias Hafner was moderated. We thank Dr. Jens Fuchser, Bruker Daltonics GmbH, Dr. Siegfried Bialoyan, Ernst & Young GmbH and Dr. Norbert-Karl Egger, Sanofi-Aventis Germany GmbH for a succinct review of the previous cooperation.

In the second part of the day, Professor Dr. Thorsten Röder an amusing online quiz, which the participants obviously liked. Subsequently, "Vision for M²Aind" was discussed in groups in terms of expectations, wishes and visions for the future. In the most beautiful weather, the respective speakers presented their results in the courtyard of Ebernburg.

We would like to thank all participants for the productive conference and look forward to the Retreat at the Ebernburg next year. We are very pleased about the good cooperation and the positive feedback on the event.

SM²all Mini Symposium 2018

Innovation Partnership M²Aind looks back on the successful "SM²all Mini Symposium 2018" on "Chemical Process Development"

On 27. June 2018 the SM²all Mini Symposium Chemical Process Development took place for the first time at the University of Applied Sciences Mannheim. Well-known companies from the healthcare industry such as BASF, CHESS, Merck, Sanofi and GSK have participated with great interest. The focus of the symposium was the scientific work of the doctoral students, who dealt intensively with the aspects of the subproject SM²all Process Development and Process Analytics and presented them to the public with great success:

  • Verena Fath, Hochschule Mannheim-University of Applied Sciences, Autonomous Process Development and Kinetic Modeling
  • Clarissa Benzin, Hochschule Mannheim-University of Applied Sciences, Chloromethane as a methylating agent in a continuous reactor
  • Torsten Klement, Hochschule Mannheim-University of Applied Sciences, Contactless kinetics measurement in a drop reactor using Raman
  • Guest lecture: Dr. Christina Rau, GlaxoSmithKline GmbH, Characterization of the interactions of drug candidates with target proteins in complex matrices
  • Rebecca Brendel, Hochschule Mannheim-University of Applied Sciences, Analysis of terpenes using ion mobility spectrometry (IMS) in complex matrices
  • Thomas Hufnagel, Hochschule Mannheim-University of Applied Sciences, Investigation of crystallization in the drop reactor by means of high-resolution Raman spectroscopy

Many thanks to Dr. Christina Rau, Cellzome/GlaxoSmithKline GmbH, for her concise guest lecture. After the very positive feedback from the participants on the event, the SM²all Mini Symposium will take place annually.

Further information about the impulse project SM²all and the project team can be found under:
www.m2aind.hs-mannheim.de/projekte/sm2all.html

MALDI Innovations in Pharma 2018

In cooperation with Bruker Daltonik GmbH, the innovation partnership M²Aind held the congress "MALDI Innovations in Pharma 2018" from 21.-22. February 2018 at the Hochschule Mannheim-University of Applied Sciences. Over two days, around 120 industry and academia representatives from the pharmaceutical, chemical and biotechnology sectors took the opportunity to network and share the latest research findings. The focus of the event was, on the one hand, mark-free high-throughput screening methods using matrix-assisted laser desorption / ionization (MALDI) mass spectrometry as well as applications of MALDI-MS imaging in the pharmaceutical industry and chemical biology. There was a great deal of interest among the audience in the various areas of application presented by the speakers in 16 lectures.
The speakers came from research companies and institutions like:

Analytik Jena (Germany), AstraZeneca (UK), Boehringer Ingelheim (Germany), Bruker Daltonics (USA), Bruker Daltonik (Germany), CeMOS (Germany), GlaxoSmithKline (UK), GlaxoSmithKline (USA), ImaBiotech (France), Inserm (France), Merck KGaA (Germany), Newcastle University (UK), Roche Pharma (Switzerland), SCiLS GmbH (Germany)

Professor Carsten Hopf, initiator of the event and head of the Competence Center CeMOS - Center for Biomedical Mass Spectrometry and Optical Spectroscopy, invited interested parties to a tour of the BMBF and DFG funded Bruker Rhein-Neckar Center for MS Fingerprinting and Imaging. Professor Hopf looks back with satisfaction on a successful congress with international lectures: "There has never been such an international congress for MALDI mass spectrometry fully tailored to the interests of the pharmaceutical industry - screening assays on the one hand and imaging for DMPK and toxicology on the other hand. The great response documents the need for these technologies, and I am glad that Bruker has organized such an event with M2Aind. "

Vice-Rector for Research and Technology Transfer of the University of Mannheim, Professor Mathias Hafner, assesses the event as a complete success for the innovation partnership M²Aind: "Due to the great interest of the industry in this event, we feel confirmed that we have set the right priorities in research; we are internationally competitive here at the highest level."

BRAIN AG and HS Mannheim are developing 3D skin models for use in the health and cosmetics industry zur Anwendung in Gesundheits- und Kosmetikbranche

Research collaboration in the M²Aind Project for New High-Resolution, Real-Time 3D Skin Spheroids Screening Technologies
Mannheim University of Applied Sciences is building on expertise in the areas of 3D cell culture and state-of-the-art live cell imaging
BRAIN is contributing unique skin reporter cells, substance test libraries and market knowledge
Review article in the Journal of Cellular Biotechnology

The research project M²Aind (Multimodal Analytics and Intelligent Sensing for the Healthcare Industry) is a public-private partnership project under the leadership of the Mannheim University of Applied Sciences, which is funded by the Federal Ministry of Education and Research (BMBF) and was launched in January 2017. From the beginning BRAIN has been an active partner in the M²Aind network. Joint projects of BRAIN and Mannheim University of Applied Sciences include the development of a skin model in 3D to better understand the physiology of the skin with the aim of opening up new application possibilities in the health and cosmetics industry. You can find the complete press release as PDF (German and English) here.

M2Aind – at the interface of biomedicine, intelligent sensors and IT

With "M2Aind", the University of Mannheim is bringing together 37 partners from large-scale industry and innovative small and medium-sized companies in the Rhine-Neckar Metropolitan Region at the interface between biomedicine, intelligent sensor technology and information technology.The partnership is based on the strong research focus "Medical Biotechnology / Medical Technology" and "Intelligent Sensor Technology", the joint institute for medical technology with the University of Heidelberg and the BMBF research campus M2OLIE.New products, services and innovative technologies for the healthcare industry are at the heart of the M2Aind partnership. The scientists are conducting research in three interlinked projects with the aim of combining highly complex technologies from the area of ​​IT-based multimodal analytics (such as imaging mass spectrometry) and intelligent sensors for new applications. Content are u. a. the biocompatibility of implantable medical technology products, drug optimization in the field of cancer, three-dimensional cell culture models for neurodegenerative diseases or the search for sugar substitutes in the focus of research and development. M2Aind addresses major health industry challenges in the areas of individualized medicine, innovative medical technology, common diseases as well as prevention and nutrition.

Here you will find the complete press release.

Source: Metropolregion Rhein-Neckar, Digital-Gipfel 2017

Innovation partnership "M²Aind" starts

The Innovation Partnership "M2Aind - Multimodal Analytics and Intelligent Sensing in the Healthcare Industry" will be officially kicked off on April 7 at 10:00 am with an opening event in the auditorium of Mannheim University of Applied Sciences. With "M2Aind", the university brings together 37 partners from the health industry from large and innovative small and medium-sized companies in the greater Rhine-Neckar-Main area. The research and work focus of the partnership is at the interface between biomedicine and information technology.The aim of "M2Aind" is to develop new products and services for the pharmaceutical, diagnostic, chemical and biotechnology industries using modular technology platforms. Highly integrated applications with a wide range of applications in IT-supported process and product analysis, organoid and tissue analysis, as well as state-of-the-art optical measurement technology are used. The focus is on various challenges in the healthcare industry. These include, for example, solutions to questions from drug testing and safety or drug discovery in tumors."The comprehensive digitization of biomolecular information and a growing understanding of molecular relationships create unimagined possibilities for a targeted and individualized diagnosis, therapy and, if necessary, treatment of common diseases", explains Prof. Dr. med. Carsten Hopf, spokesman for the partnership and head of the Institute for Instrumental Analysis and Bioanalytics. During the opening, Prof. Hopf and the project leaders, professors dr. Thorsten Röder, dr. Matthias Rädle, dr. Rudiger Rudolf and dr. Mathias Hafner, the partnership concept and the three linked projects. The existing strong research areas "Medical Biotechnology / Medical Technology" and "Intelligent Sensor Technology" as well as the joint institute for medical technology with the University of Heidelberg form the University of

Here you will find the complete press release.

Source: Gesundheitsindustrie BW

Further press releases

Mentioned 2016 / Kick-Off 2017

April 2017, Press release of the University of Mannheim

March 2017, biospectrum

November 2016, University of Mannheim

November 2016, MRN News

August 2016, Rhein Neckar newspaper

August 2016, Bioeconomy BW

August 2016, business magazine Econo

August 2016, Press release of the Ministry of Science, Research and Art Baden-Württemberg

July 2016, Press release of the University of Applied Sciences Baden-Württemberg

July 2016, Mannheimer Morgen

July 2016, City of Mannheim Cluster Medizintechnologie

July 2016, Press release of the University of Mannheim

July 1016, Press release of the BMBF

November 2015, Press release of the University of Mannheim